HistoGenetics Selects Illumina’s MiSeq® System as Next-Generation Sequencing Platform of Choice

  HistoGenetics Selects Illumina’s MiSeq® System as Next-Generation Sequencing
  Platform of Choice

    MiSeq Will Supplement HistoGenetics’ Existing Human Leukocyte Antigen
                            Sequence-Based Typing

Business Wire

SAN DIEGO & NEW YORK -- July 22, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced that HistoGenetics, the leader in
high-resolution sequence-based human leukocyte antigen (HLA) testing services,
has selected the MiSeq sequencing system for use in its CLIA laboratory.
HistoGenetics will deploy multiple MiSeqs to supplement its existing Sanger
sequencing workflow to sequence HLA genes with high accuracy and speed. In
addition to their utility in tissue matching for transplants, HLA gene
variations have known associations with a wide variety of autoimmune diseases,
infectious diseases, and some cancers.

Despite their importance, HLA genes have not been routinely typed at higher
resolution because of the technical challenges of accurately discriminating
between these highly related genes and their many alleles. HistoGenetics, one
of the largest HLA typing laboratories in the world, has previously
implemented Sanger sequencing as the sole method for higher resolution HLA
typing. With its deployment of MiSeqs, HistoGenetics will lead the transition
from Sanger sequencing to next-generation sequencing for HLA typing.

“We anticipate building on our leadership position and established success by
leveraging the MiSeq platform,” said Dr. Nezih Cereb, Chief Executive Officer
and Co-founder of HistoGenetics. “Based on our experience with other
technologies, we think the MiSeq’s quality data output and simple workflow,
combined with Illumina’s commitment to work collaboratively, is the ideal
solution to enable us to provide our customers with the superior results and
turnaround time they require.”

HistoGenetics currently provides two levels of resolution with HLA
sequencing-based testing, including high-level and registry-level resolution.
At high resolution, the most comprehensive level, all ambiguities are resolved
in the antigen recognition sites, and new and rare alleles missed by other
methods typically can be found. The American Society for Histocompatibility
and Immunogenetics and the National Marrow Donor Program require this level of
testing for stem cell transplants. At the registry level, which is used for
unrelated donor registries (such as the Be The Match Registry^TM) and cord
blood banks, a majority of ambiguities are resolved.

“By introducing the MiSeq, we will be able to provide gold-level high
resolution typing to pre-transplant work-ups, as well as to registry donors,
and improve the turnaround time for sample processing,” added Dr. Cereb.

HistoGenetics’ turnaround time for typing services is currently as short as
three days for urgent samples. To date, HistoGenetics has typed more than 3
million samples and performed more than 13 million sequence-based typings that
led to the discovery of more than 16,000 samples carrying a new variant of an
HLA allele.

“Next-generation sequencing has the potential to transform HLA genotyping, and
we believe Illumina’s technology is well-positioned to help drive that
change,” said Matt Posard, Senior Vice President and General Manager of
Illumina's Translational and Consumer Genomics business. “The MiSeq can make a
significant difference in terms of accuracy and speed for production-scale HLA
typing. We look forward to a successful relationship with HistoGenetics.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

About HistoGenetics, LLC

HistoGenetics (www.histogenetics.com) is the global leader in HLA
sequence-based typing (SBT). As a pioneer the field, the company has provided
its services for donor registries, donor centers, cord blood typing,
transplant centers, HLA laboratories and pharmacogenomics applications. To
date, HistoGenetics has performed more than 13 million SBTs and discovered
16,000 samples carrying new alleles. The company was founded by Dr. Soo Young
Yang, who serves as Chairman, and Dr. Nezih Cereb, Chief Executive Officer.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.